Joel Fluss
Research Subjects
Joel Fluss has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
D. Geary
The Hospital for Sick Children
1 shared publicationDenis Geary
The Hospital for Sick Children
1 shared publicationG. de Veber
The Hospital for Sick Children
1 shared publication- Gabrielle Deveber
From the Section of Neurology (M.F.R.), Department of Pediatrics and Child Health, University of Manitoba, the Population Health Sciences Program (M.F.R., A.-M.P., J.C., M.A., G.A.d.V.), the Division of Emergency Medicine (D.A.J.), and the Division of Neurology (D.M., G.A.d.V.), The Hospital for Sick Children, Toronto, Ontario, Canada; and the Division of Neurology (F.S.), University Health Network, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- 19 April 2007
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 166 (7) , 759
Reply to correspondence letter: cerebral sinovenous thrombosis in a child with steroid-sensitive nephrotic syndrome
- 19 April 2007
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 166 (7) , 759
Reply to correspondence letter: cerebral sinovenous thrombosis in a child with steroid-sensitive nephrotic syndrome
- 12 May 2006
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 165 (10) , 709-716
Cerebral sinovenous thrombosis and idiopathic nephrotic syndrome in childhood: report of four new cases and review of the literature
Nephrotic children are prone to develop thromboembolic complications secondary to an acquired hypercoagulable state. Cerebral sinovenous thrombosis (CSVT) is increasingly recognised in this population, but clinical characteristics and outcome are not well documented. The database of the Canadian Pediatric Ischemic Stroke Registry (Toronto Site) containing prospectively enrolled children from 1992–2004 with CSVT identified four children with NS. A pooled literature analysis retrieved 17 additional cases reports. CSVT presented in the majority of cases during the first flare or within 6 months after the onset of NS and was found to occur more often in SSNS/SDNS (n=13) than in SRNS (n=4). Clinical manifestations were non-specific and consisted primarily of seizures (n=8) and signs of raised intracranial pressure (n=16). Imaging studies revealed a predilection for superior sagittal sinus involvement (n=21) and rare parenchymal lesions (n=4). The most consistent biological risk factors were a severe hypoalbuminaemia (n=14) and, to a lesser extent, decreased antithrombin (AT) levels (n=9/16). Deficiency of other coagulation inhibitors (protein S, protein C) was not identified. Inherited thrombophilia was documented in a single case, suggesting that acquired, more than genetic, coagulation factors are involved. Anticoagulation was safe, and the outcome was good in most patients, and no recurrence of thrombotic event was reported. In conclusion, CSVT is now a well-described complication of NS with potential morbidity. A high index of suspicion is required, especially in young children with NS presenting neurological symptoms. Reliable biological predictors of CSVT are lacking.
- 12 May 2006
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 165 (10) , 709-716
Cerebral sinovenous thrombosis and idiopathic nephrotic syndrome in childhood: report of four new cases and review of the literature
Nephrotic children are prone to develop thromboembolic complications secondary to an acquired hypercoagulable state. Cerebral sinovenous thrombosis (CSVT) is increasingly recognised in this population, but clinical characteristics and outcome are not well documented. The database of the Canadian Pediatric Ischemic Stroke Registry (Toronto Site) containing prospectively enrolled children from 1992–2004 with CSVT identified four children with NS. A pooled literature analysis retrieved 17 additional cases reports. CSVT presented in the majority of cases during the first flare or within 6 months after the onset of NS and was found to occur more often in SSNS/SDNS (n=13) than in SRNS (n=4). Clinical manifestations were non-specific and consisted primarily of seizures (n=8) and signs of raised intracranial pressure (n=16). Imaging studies revealed a predilection for superior sagittal sinus involvement (n=21) and rare parenchymal lesions (n=4). The most consistent biological risk factors were a severe hypoalbuminaemia (n=14) and, to a lesser extent, decreased antithrombin (AT) levels (n=9/16). Deficiency of other coagulation inhibitors (protein S, protein C) was not identified. Inherited thrombophilia was documented in a single case, suggesting that acquired, more than genetic, coagulation factors are involved. Anticoagulation was safe, and the outcome was good in most patients, and no recurrence of thrombotic event was reported. In conclusion, CSVT is now a well-described complication of NS with potential morbidity. A high index of suspicion is required, especially in young children with NS presenting neurological symptoms. Reliable biological predictors of CSVT are lacking.